Archive Newsletter
-
05.09.24 -- Frankly Fran: Organizational Imperatives For Combination Product Development
5/9/2024
05/09/24 Drug Delivery Leader Newsletter
-
05.06.24 -- Long Live Design Controls: Navigating The Shift From QSR To QMSR
5/6/2024
05/06/24 Drug Delivery Leader Newsletter
- Best of April: Top 5 Insights in Drug Formulation and Delivery 5/1/2024
-
04.29.24 -- A Promising Approach To Develop An Inhalable, Temperature-Stable COVID-19 Vaccine
4/29/2024
04/29/24 Drug Delivery Leader Newsletter
-
04.22.24 -- Tackling 3 Challenges In Developing An Inhaled Gene Therapy
4/22/2024
04/22/24 Drug Delivery Leader Newsletter
-
04.15.24 -- Navigating EU MDR Compliance: Overcoming Challenges To Sustain Your Certification
4/15/2024
04/15/24 Drug Delivery Leader Newsletter
-
04.08.24 -- Exploring Biolistic Particle Delivery Systems
4/8/2024
04/08/24 Drug Delivery Leader Newsletter
- Best of March: Top 5 Insights in Drug Formulation and Delivery 4/5/2024
-
04.01.24 -- New FDA QMSR Through The Lens Of Risk Management: Requirements And Analysis
4/1/2024
04/01/24 Drug Delivery Leader Newsletter
-
03.25.24 -- Use-Related Risk Analysis For Combination Products
3/25/2024
03/25/24 Drug Delivery Leader Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more